课题基金 / 基金详情

Development of a thermostable rotavirus vaccine for mucosal delivery without need for reconstitution

Development of a thermostable rotavirus vaccine for mucosal delivery without need for reconstitution
开发用于粘膜递送且无需重构的热稳定性轮状病毒疫苗
批准号:
8903047
负责人:
Victor Bronshtein
金额:
$14.8万
依托单位国家:
美国
项目类别:
财政年份:
2015
资助国家:
美国
项目状态:
已结题
起止时间:
2015-02-10 至 2016-04-30

项目摘要

项目成果

Victor Bronshtein的其他基金

相似基金

相关文献

中文摘要
翻译
 描述(申请人提供):轮状病毒是全球儿童严重脱水腹泻的主要原因,每年造成约50万人死亡,其中大部分是发展中国家的五岁以下儿童。最近,两种轮状病毒活疫苗RotaTeq(默克)和Rotarix(葛兰素史克)已被批准用于婴儿。重要的是,这些疫苗的运输和储存都需要冷链,在它们目前的多剂量液体配方中,这些疫苗的储存空间要求是脊髓灰质炎疫苗的五到二十倍。因此,迫切需要开发一种成本效益高、干燥、环境温度稳定、有效且不需要重建的轮状病毒疫苗。巴拉特生物技术公司已经开发出一种轮状病毒减毒活疫苗(Rotavac),并计划以每剂1.00美元的价格向全球公开市场销售。这种疫苗是作为公私合作项目开发的,预计将于2014年获得印度许可,并于2015年获得世卫组织向联合国机构供应的资格预审。Rotavac的临床研究已经证明,在印度儿童中,分三次口服Rotavac是安全、免疫原性和有效的;然而,Rotavac必须冷藏以保持稳定性。通用稳定技术公司(UST)已经开发并证明了其创新的、正在申请专利的汽化保鲜(PBV)技术的商业价值。科大已经证明,许多生物制品,包括活病毒和细菌,以及抗体、酶、凝血因子和其他蛋白质,在经过PBV处理后,在环境温度下保持高活性和长期稳定性,并可以在70°C或更高温度下短期(1小时或更长时间)暴露。拟议的技术开发--一种干燥、耐热、速溶的Rotavac口腔口腔膜剂--将使疫苗生产变得更便宜,因为PBV可能提高产量,而且由于PBV配方不需要冷链,因此降低了分发和储存成本。通过将干燥、耐热的Rotavac疫苗配制为口服用的速溶薄膜,将进一步节省成本。与目前市场上的液体配方相比,薄膜配方还将为婴儿提供更准确的剂量和更容易的管理。该第一阶段项目的具体目标是1)开发一种使用PBV技术制造干式耐热轮状病毒疫苗的配方和工艺,以及2)制造含有适合口服的干式耐热轮状病毒疫苗的速溶薄膜。在……里面 在该项目的第二阶段,科大科技大学将在动物模型中评估干式耐热轮状病毒疫苗速溶薄膜制剂的免疫原性和保护效果。该项目的长期目标是生产一种用于婴儿口服的轮状病毒疫苗的速溶薄膜制剂,该制剂具有环境温度稳定、免疫原性、保护性和低制造、储存和运输成本。
英文摘要
 DESCRIPTION (provided by applicant): Rotavirus is the leading cause of severe dehydrating diarrhea in children worldwide, and is responsible for an estimated 500,000 deaths each year, mostly in children under the age of five years in developing countries. Recently, two live rotavirus vaccines, RotaTeq (Merck) and Rotarix (Glaxo Smith Kline), have been approved for use in infants. Importantly, both transportation and storage of these vaccines require a cold chain, and in their current multi-dose liquid formulations, the storage space requirements for these vaccines are five to twenty times higher than for polio vaccine. Thus there is an urgent need to develop a cost-effective rotavirus vaccine that is dry, ambient temperature-stable, potent, and does not require reconstitution. Bharat Biotech has developed a live attenuated rotavirus vaccine (Rotavac) and plans to sell it to global public markets at a price of US $1.00 per dose. This vaccine was developed as a public-private partnership project and is expected to receive India licensure in 2014 and WHO Prequalification in 2015 for supply to UN agencies. Clinical studies with Rotavac have demonstrated safety, immunogenicity, and efficacy in Indian children when administered orally in three doses; however, Rotavac must be refrigerated to maintain stability. Universal Stabilization Technologies, Inc. (UST) has developed and proven commercial value of its innovative, patent-pending Preservation by Vaporization (PBV) technology. UST has demonstrated that many biologicals, including live viruses and bacteria, as well as antibodies, enzymes, coagulation factors, and other proteins, retain high activity and long-term stability at ambient temperatures after processing by PBV and can survive short-term (1 hour or longer) exposure to 70°C or higher temperatures. The proposed technology development-a dry, thermostable, quick-dissolving oral buccal film formulation of Rotavac-will allow cheaper vaccine production because of the enhanced yields possible with PBV as well as reduced distribution and storage costs because PBV formulations do not require a cold chain. Further cost savings will be achieved by formulating the dry, thermostable Rotavac vaccine as a quick-dissolving film for oral administration. A film formulation will also provide more accurate dosing and easier administration to infants than the current liquid formulations on the market. The specific objectives of this Phase I project are 1) develop a formulation and process for manufacturing dry thermostable rotavirus vaccine using PBV technology, and 2) manufacture quick-dissolving films containing dry thermostable rotavirus vaccine suitable for oral delivery. In Phase II of this project, UST will assess the immunogenicity and protective effects of the quick-dissolving film formulation of dry thermostable rotavirus vaccine in animal models. The long-term goal of this project is to generate a quick-dissolving film formulation of rotavirus vaccine fr oral delivery to infants that is ambient temperature-stable, immunogenic, protective, and low cost to manufacture, store, and ship.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Thermostable Inactivated Potent Yellow Fever Vaccine
Development of a thermostable rotavirus vaccine for mucosal delivery withoutneed for reconstitution - Phase II
Thermostable vaginal probiotic microbicide
Thermostable vaginal probiotic microbicide
国内基金
海外基金
补阳还五汤通过AGE-RAGE通路调控脓毒症免疫失衡的机制与转化研究
芹菜素通过AGE-RAGE通路抑制干眼的炎症与氧化应激
  • 批准号:
    82505677
  • 项目类别:
    青年科学基金项目(C类)
  • 资助金额:
    30.00万元
  • 批准年份:
    2025
  • 负责人:
    吕雨霏
  • 依托单位:
麝香通心滴丸通过干预AGE-RAGE轴调节O-GlcNAc修饰发挥防治DCM作用的药效物质及机制研究
  • 批准号:
    82574874
  • 项目类别:
    面上项目
  • 资助金额:
    49.00万元
  • 批准年份:
    2025
  • 负责人:
    刘天华
  • 依托单位:
靶向递送一氧化碳调控AGE-RAGE级联反应促进糖尿病创面愈合研究
  • 批准号:
    JCZRQN202500010
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2025
  • 负责人:
  • 依托单位: